<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00064363</url>
  </required_header>
  <id_info>
    <org_study_id>030207</org_study_id>
    <secondary_id>03-C-0207</secondary_id>
    <secondary_id>CDR0000315425</secondary_id>
    <nct_id>NCT00064363</nct_id>
    <nct_alias>NCT00061685</nct_alias>
  </id_info>
  <brief_title>Talampanel in Treating Patients With Recurrent High-Grade Glioma</brief_title>
  <official_title>A Phase II Trial Of Talampanel In Patients With Recurrent High-Grade Gliomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institutes of Health Clinical Center (CC)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy such as talampanel use different ways to stop tumor&#xD;
      cells from dividing so they stop growing or die.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well talampanel works in treating patients with&#xD;
      recurrent, progressive high-grade glioma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the efficacy of talampanel, in terms of 6-month progression-free survival, in&#xD;
           patients with recurrent high-grade gliomas.&#xD;
&#xD;
        -  Determine, preliminarily, the toxic effects of this drug in these patients.&#xD;
&#xD;
        -  Determine, preliminarily, the quality of life of patients treated with this drug.&#xD;
&#xD;
        -  Determine the pharmacokinetics of this drug in patients who are and who are not&#xD;
           receiving enzyme-inducing antiepileptic drugs.&#xD;
&#xD;
      OUTLINE: Patients are stratified according to type of glioma (anaplastic astrocytoma vs&#xD;
      glioblastoma multiforme). Patients in each stratum are assigned to 1 of 3 treatment groups&#xD;
      according to concurrent enzyme-inducing antiepileptic drug use (yes, no, or valproic acid).&#xD;
&#xD;
      Patients in each group receive different doses of oral talampanel 3 times daily on days 1-42.&#xD;
      Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Quality of life is assessed at baseline, every 3 weeks during the first course, every 6 weeks&#xD;
      before all subsequent courses, and then within 2 weeks of study completion.&#xD;
&#xD;
      Patients are followed within 2 weeks.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 91 patients (50 with anaplastic astrocytoma and 41 with&#xD;
      glioblastoma multiforme) will be accrued for this study within 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2003</start_date>
  <completion_date type="Actual">February 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression at 6 months</measure>
  </primary_outcome>
  <condition>Brain and Central Nervous System Tumors</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>talampanel</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed high-grade glioma, including any of the following:&#xD;
&#xD;
               -  Glioblastoma multiforme&#xD;
&#xD;
               -  Anaplastic astrocytoma&#xD;
&#xD;
               -  Anaplastic oligodendroglioma&#xD;
&#xD;
               -  Anaplastic mixed oligoastrocytoma&#xD;
&#xD;
               -  Malignant astrocytoma not otherwise specified&#xD;
&#xD;
                    -  Patients with clinical and radiographic diagnosis of brain stem glioma are&#xD;
                       also eligible&#xD;
&#xD;
          -  Evidence of tumor progression by MRI or CT scan&#xD;
&#xD;
               -  Scan must be performed while patient is on a stable steroid dose for at least 5&#xD;
                  days&#xD;
&#xD;
          -  Must have failed prior radiotherapy&#xD;
&#xD;
          -  Residual disease after prior resection of recurrent or progressive tumor is allowed&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  More than 8 weeks&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count greater than 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3 (transfusion independent)&#xD;
&#xD;
          -  Hemoglobin at least 10 g/dL (transfusion allowed)&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin less than 2 times upper limit of normal (ULN)&#xD;
&#xD;
          -  SGOT less than 2 times ULN&#xD;
&#xD;
          -  No significant active hepatic disease&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine less than 1.5 mg/dL OR&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
          -  No significant active renal disease&#xD;
&#xD;
        Cardiac&#xD;
&#xD;
          -  No significant active cardiac disease&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use 2 effective methods of contraception during and for 2 months&#xD;
             after study participation&#xD;
&#xD;
          -  Able to swallow whole capsules&#xD;
&#xD;
          -  No active infection requiring IV antibiotics&#xD;
&#xD;
          -  No significant active psychiatric disease that would preclude use of the study drug&#xD;
&#xD;
          -  No other significant uncontrolled medical illness that would preclude study&#xD;
             participation&#xD;
&#xD;
          -  No other active life-threatening malignancy&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  At least 1 week since prior interferon or thalidomide&#xD;
&#xD;
          -  No concurrent anticancer immunotherapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  At least 2 weeks since prior vincristine&#xD;
&#xD;
          -  At least 3 weeks since prior procarbazine&#xD;
&#xD;
          -  At least 6 weeks since prior nitrosoureas&#xD;
&#xD;
          -  No other concurrent anticancer chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 1 week since prior tamoxifen&#xD;
&#xD;
          -  Concurrent steroids for the control of increased intracranial pressure allowed&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy&#xD;
&#xD;
          -  No concurrent anticancer radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Prior recent resection of recurrent or progressive disease allowed&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Recovered from all prior therapy&#xD;
&#xD;
          -  At least 1 week since prior noncytotoxic agents (e.g., isotretinoin), except for&#xD;
             radiosensitizers&#xD;
&#xD;
          -  At least 4 weeks since prior investigational agents&#xD;
&#xD;
          -  At least 4 weeks since prior cytotoxic therapy&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Howard A. Fine, MD</last_name>
    <role>Study Chair</role>
    <affiliation>NCI - Neuro-Oncology Branch</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Iwamoto FM, Kreisl TN, Kim L, Duic JP, Butman JA, Albert PS, Fine HA. Phase 2 trial of talampanel, a glutamate receptor inhibitor, for adults with recurrent malignant gliomas. Cancer. 2010 Apr 1;116(7):1776-82. doi: 10.1002/cncr.24957.</citation>
    <PMID>20143438</PMID>
  </results_reference>
  <verification_date>March 2012</verification_date>
  <study_first_submitted>July 8, 2003</study_first_submitted>
  <study_first_submitted_qc>July 8, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2003</study_first_posted>
  <last_update_submitted>March 7, 2012</last_update_submitted>
  <last_update_submitted_qc>March 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 8, 2012</last_update_posted>
  <keyword>recurrent adult brain tumor</keyword>
  <keyword>adult anaplastic astrocytoma</keyword>
  <keyword>adult glioblastoma</keyword>
  <keyword>adult anaplastic oligodendroglioma</keyword>
  <keyword>adult mixed glioma</keyword>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <keyword>adult brain stem glioma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

